We use cookies to ensure that we give you the best experience on our website Learn more

Jun 27, 2018

MASCC/ISOO Annual Meeting on Supportive Care in Cancer

09 / WHAT OCCURS IN THE OTHER 20% OF CANCER PATIENTS WITH CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING? A SINGLE INSTITUTION QUALITATIVE STUDY

Childs;

D.;

Looker;

S.;

Le-Rademacher;

J.;

Ridgeway;

J.;

Radecki Breitkopf;

C.;

Jatoi;

A.

nausea and vomiting

emetogenic

underreporting

qualitative

supportive care

Abstract

Abstract

thumbnail

Keywords

nausea and vomiting

emetogenic

underreporting

qualitative

supportive care

Abstract

Introduction: Despite major advances in prophylaxis and management, 20% of patients who receive moderately to severely emetogenic chemotherapy continue to experience nausea and vomiting (N/V). Objectives: In the current era of “highly effective antiemetic therapy,” this qualitative study sought to fill a void in the published literature by capturing and characterizing the lived experience with chemotherapy-induced N/V in patients’ own words. Methods: Solid tumor patients with a history of poorly controlled N/V provided informed consent and then participated in a semi-structured interview, which was audio-recorded and transcribed. After data saturation, enrollment ceased; and inductive, qualitative analytic methods were employed. Results: The median age of these 20 patients was 56 years (range: 27, 83) with an equal gender split; half had gastrointestinal cancers. Two themes emerged. First, N/V remains a severe and multidimensional experience: “It’s like shredding your muscles… It’s doing it over and over again.” This symptom complex has psychosocial implications: “Isolation is a big thing.” Financial toxicity is also implicated: “I use [antiemetics] when I feel like it is absolutely necessary because it is so expensive I cannot afford it anyway.” The second theme is under reporting; patients seemed to accept N/V and therefore underreport to providers: “God, if you’re pumping poison in your system, you gotta expect some side effects.” Conclusions: These vivid data should motivate investigators to continue conducting clinical trials for CINV and should remind healthcare providers about the importance of patient education on the availability of therapy for breakthrough symptomatology.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.